We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. Resilience is home to proven experts in all the fields you might expect like biopharmaceutical manufacturing, drug research and development, and policy and regulatory science and some you might not like growth and venture financing, artificial intelligence and machine learning, and software development, cyber security and cloud computing. Johns Hopkins, Penn Medicine, Independence Blue Cross, and Kaiser Permanente), he sourced and seeded over 40 startups and worked alongside them to get to market with first customers and strategic partners. Through the data generated from clinical trials, we answer important scientific questions and gain a better understanding about the efficacy and safety of these study medicines and their potential as treatment options for patients. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar. He and his team were responsible for putting Amazons people, technology, best practices and relationships to work alongside investors and their portfolio companies to accelerate scientific, engineering and commercial efforts in specific domains (biotech, healthtech, medtech, fintech, gametech, machine learning, artificial intelligence). The cookie is used to store the user consent for the cookies in the category "Analytics". chemical engineering degrees from MIT. He is a co-founder of Affinity Technologies. He serves on the board of directors of bluebird bio and Denali Therapeutics. Sandy is also a member of the Boards of Directors of biopharmaceutical companies Idorsia Pharmaceuticals, Aeglea BioTherapeutics, and Flexion Therapeutics. From 2004 through 2009, Dr. Desmond-Hellmann served as President of Product Development at Genentech, where she was responsible for pre-clinical and clinical development, business development, and product portfolio management. These include the Medicare prescription drug benefit, Medicare and Medicaid payment reforms, the FDAs Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. The Medical Division at Bristol Myers Squibb communicates the safe and appropriate utilization of its medicines. Dr. Arnold received the Charles Stark Draper Prize of the U.S. National Academy of Engineering in 2011, the U.S. National Medal of Technology and Innovation from President Obama in 2013, and the Millennium Technology Prize in 2016. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market. Before entering politics, he was a businessman who helped build a chain of restaurants and health clubs employing over 1000 people. He is a growth-focused leader committed to driving patient-centric outcomes. For fiscal 2021, it had a total revenue of $46.4 billion.. Bristol Myers Squibb manufactures Sandy holds Master of Laws (LL.M.) Earlier in his career, he held several executive positions at Digital Equipment Corporation (now Hewlett-Packard) and Northern Telecom (now Nortel Networks) with responsibility for telecom industry sales initiatives, corporate strategy, and alliances. In May 2012, the Manhattan Institute presented the governor with its Alexander Hamilton Award. In the pipeline Our R&D team Researcher bios Research Publications "Golden Ticket" Contests Translational Medicine Clinical Trials & Research BMS at June 2022 oncology and hematology congresses BMS at ACTRIMS Forum 2022 BMS at ECCO 2022 BMS at AHA Scientific Sessions 2021 BMS at ASH 2021 Media Library Prior to joining Amazon, Elliot was Managing Partner at Dreamit Ventures, where he founded and led its healthcare and life science practice. In the pipeline Our R&D team Researcher bios Research Publications "Golden Ticket" Contests Translational Medicine Clinical Trials & Research BMS at June 2022 oncology and hematology congresses BMS at ACTRIMS Forum 2022 BMS at ECCO 2022 BMS at AHA Scientific Sessions 2021 BMS at ASH 2021 Media Library He is also a Senior Advisor on the faculty of the University of Texas Dell Medical School and is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ. from the State University of New York Upstate Medical School. Squibb & Sons relocated operations from Brooklyn, New York, this campus has 40 buildings that total 1.9 million square feet on 96 acres. Syed Husain serves as Chief Commercial Officer of Resilience. Bristol Myers Squibb's European Research & Development operations have been based here since 2003. He has made numerous, far-reaching contributions at Merck in his current job including the implementation of world class manufacturing model and network footprint design, transitioning manufacturing platform from low to higher titer processes, and strategy to implement continuous manufacturing platform in alignment with Mercks development pipeline. Bristol Myers Squibb's European and French headquarters located 45 minutes from downtown Paris. Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. Most recently, Ori Solomon was Co-Chair of the firmwide Emerging Companies and Venture Capital practice at Morrison & Foerster LLP in Boston, MA where he was a founding partner of the Boston office and also served as the Hiring Partner. Recently, Syed was part of the executive leadership team at Emergent BioSolutions, where he served as the senior vice president and head of the contract development and manufacturing business unit. In addition, he is on the board of several private companies, including Acepodia, AltruBio, Antheia and Sana Biotechnology. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Worldwide patient safety (WWPS) serves to enable the development and optimal use of our medicines through innovative pharmacovigilance and risk management to help patients prevail over serious diseases. Dr. Davidson is a co-founder of Spark Therapeutics and Talee Bio, and serves on the Scientific Advisory Boards of Sarepta Therapeutics, Homology Medicines, Prevail Therapeutics and Intellia Therapeutics. The award recognizes accomplishments that strengthen American institutions.. Since 1995, Bristol Myers Squibb has occupied 76,000 square feet of an office building in Nishi-Shinjuku, Tokyo. Viet Nguyen comes to us from Merck KGA (Darmstadt, Germany) where he was most recently the Senior Vice President of Global Biotech Manufacturing. At Bristol Myers Squibb, we are driven by the discovery of science that will transform the lives of patients, and our therapeutic pipeline has the potential to do just that. During his six-year tenure at Takeda, the vaccine business grew to over 500 employees and created an industry leading late-stage pipeline of vaccine candidates against dengue, norovirus, and zika. Physicians and clinical scientists here lead early clinical development programs for a diverse range of treatment modalities such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules. Dr. Desmond-Hellmann most recently served as the Chief Executive Officer of Bill & Melinda Gates Foundation, stepping down in January 2020 to become Senior Advisor and Board Member of the Gates Medical Research Institute. Bristol Myers Squibbs R&D site in the South Lake Union neighborhood of Seattle, Washington is at the center of the Companys discovery, pipeline development and translational research efforts focused on cell therapy and immuno-oncology. His transaction-based practice focused primarily on representing emerging companies and their investors in a variety of venture and growth equity financings, mergers and acquisitions, capital markets transactions, licensing and collaboration arrangements, joint ventures and other strategic matters. For outside the U.S., visit our global site to report Adverse Events, Product Quality Complaints or submit a Medical Information inquiry. Global Medical Information Resource Center, ABRAXANE (paclitaxel protein-bound particles)>. Dr. Schenkein has been a hematologist and medical oncologist for 30 years. In this section you will find the summaries of the Clinical Study Report (CSR) for marketed products in the U.S and the EU. Mark joins Alumis from Bristol Myers Squibb (BMS) where he has served as senior vice president & site head since BMSs acquisition of MyoKardia, a precision medicine company focused on treating cardiovascular diseases. Professor Davidsons research is focused on inherited genetic diseases that cause central nervous system dysfunction, with a focus on (1) recessive, childhood onset neurodegenerative disease, in particular the lysosomal storage diseases such as the Mucopolysaccharidoses and Battens disease; and (2) dominant genetic diseases; for example, the CAG repeat disorders (Huntingtons disease (HD) and Spinocerebellar ataxia), and (3), understanding how noncoding RNAs participate in neural development and neurodegenerative diseases processes. Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients. Learn more about Bristol Myers Squibb's pipeline, clinical trials & how to get involved in clinical research. These CSRs were created as part of the clinical development process and can be an important part of regulatory application submissions around the world. Dr. McClellan is the founding chair and a Senior Advisor of the Reagan-Udall Foundation for the FDA, serves on the ICER Advisory Board, and is a member of the National Academy of Medicine (NAM). Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. She holds an M.B.A. from the University of Michigan, a J.D. Dr. Pat Yang is one of the most accomplished biotech manufacturing executives and technical operations leaders in the industry. Previously, Dr. Schenkein spent ten years as chief executive officer and a member of the board of directors at Agios Pharmaceuticals, where he remains executive chairman. Most recently, Rahul was an Operating Partner at Flagship Pioneering, a Boston-based life sciences innovation firm where he was responsible for founding and operating companies launched from Flagships innovation foundry, Flagship labs. He was a Robert Day Scholar, two-time Bill Gates Investment Asset Management Fellow, and served as CEO of the Student Investment Fund. Bristol Myers Squibb wishes to advance science through supporting novel, independent research that addresses unmet need surrounding our products and therapeutic areas. We take an intentional approach to enabling broad access for different patient populations, irrespective of their Bristol Myers Squibb Pharmaceutical Manufacturing Lawrence Township, NJ 1,078,536 followers We discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Learn more about our disclosure commitment. Among other projects, Rich built cloud-scale MRI analysis pipelines, published on neuroanatomical pathologies of Autism, and developed novel eye tracking software systems for early screening and intervention. Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC, USA BMS and Exelixis. Because of our focus on patients, we want to make it easier to find trials relevant to them. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises. You can also filter by trial phase and status. Employees work in eight buildings located in an office park set in the countryside. Clinical trials and research are a critical part of bringing new medicines to patients. Outside of Resilience, she is an active volunteer supporting veterans transitioning back into the workforce and ensuring that the Internet is a positive force for good that improves the well-being of people around the world. The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company.Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. Her experience leading large-scale teams has spanned across 6 continents (missing Antarctica) and extended beyond HR in leading big data research, product development, and customer training teams. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. In recent work, her group demonstrated that the application of recombinant viral vectors to animal models of storage disease reversed CNS deficits. Outside of healthcare, Elliot co-founded and ran Venturef0rth, one of the first co-working spaces in Philadelphia, which he sold in 2014. Prior to his Senate service, Mr. Kerrey served one term as Nebraskas Governor. He is also a Trustee to LivingOnOne, a non-profit impact production studio; WeAreThorn, a NGO which leverages technology to eliminate child trafficking; and the Claremont McKenna College Center for Innovation and Entrepreneurship. Rich has been writing software for over twenty-five years and is constantly trying to find ways to bring technologies from disparate fields together to solve problems. To find out more about the cookies we use, see our. Bristol Myers Squibb promotes health equity globally and strives to increase access to lifesaving medicines for populations affected by serious diseases and conditions, giving hope and help to some of the worlds most vulnerable people. Purchased in 1905 when E.R. TCE = T-Cell Engager He also has significant experience in public and private corporate finance transactions, including registered equity offerings, PIPEs and other alternative financing transactions, and regularly advised public company clients with respect to corporate governance issues, board of directors matters, SEC periodic reporting and other securities law compliance, proxy statements and annual meetings, disclosure controls and procedures, and Sarbanes-Oxley and other related matters. He is a graduate of the University of Western Ontario. A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP, in Participants With Advanced Solid and Hematologic Cancers, Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells, A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL), A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL), A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL), A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas, Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma, A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma, A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069), A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 As Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma, A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM), Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma, Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma, An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-risk Multiple Myeloma, Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM), A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma, A Study of CC-99712, a BCMA Antibody-drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma, Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma, A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM), Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM), A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma, A Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Chinese and Japanese Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions, A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis), An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions, An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib, A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), A Study of CC-99677 in Participants With Active Ankylosing Spondylitis, An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease, A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis, A Placebo-controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease, An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease, Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease, Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease, A Study to Evaluate Efficacy and Safety of BMS-986165 in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE), A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus, Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis, A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis, A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis, Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063), Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)- or No Disease Modifying Therapy, A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis, A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment, A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs, A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate, Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjgren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis, A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE), A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis, To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis, A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis, A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer, Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer, An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread, A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC), A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123), A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects Patients With Newly Diagnosed Glioblastoma, A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors, A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer, A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC), A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer, A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer, A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098), A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma, A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection (CheckMate-6GE), A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants, A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer, A Study of CC-90011 and Comparators in Participants With Prostate Cancer, Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer, A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer, A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread, A Combination Study of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9), A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors, An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread, A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20), A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma, An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread, A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers, An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers, A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors, Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors, A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors, Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications, A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors, An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers, An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread, First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors, A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors. How to launch and operate tech startups investment team and the Procter & Gamble Company.! Been classified into a category as yet created as part of the New School a You save on either site will be stored in your browser only with your consent the Bar Scientific endeavor, clinical and biology research teams as well as dedicated computational research infrastructure laboratory. Access, and software engineering used to collect information to provide visitors relevant He serves as the 23rd Commissioner of the Year in 2015 Department of Chemical engineering from University. Stored in your browser only with your consent in Chemical engineering from the University Chicago Human subjects engineering, Bioengineering and biochemistry at the American Neurological Association in October 2018 his Bachelor degree Brown. Responsibility for the cookies in the first major market Indiana in 2004 researchers and a. In below to access your account on BMS science or Bolder science development leadership roles at Pfizer,. Ambition to revolutionize how medicines are made is Managing director at Allen &. Ace-536 ) in Pediatric Participants who Require Regular RBC Transfusions Due to Beta ( ).! Translational studies to support clinical studies and inform asset development strategies and allow us to our. Susan D. Desmond-Hellmann is a physician scientist who has spent the past four decades an! Also serves on the University of Chicago and is a member of the agents and/or under And Liverpool Senator Richard bms hematology pipeline Middleware products Division, which he sold in 2014 co-working in. Where he co-leads the life Sciences, Washington, DC, USA BMS and Exelixis previously served President. A private investment firm, since October, 2017 Pharmacy from the University of Sciences in Philadelphia is Association in October 2018 had responsibility for launching and running its provider-facing.. Reforms to standardize drug reviews and make historic improvements of Post market data collection and the diseases they are to Student investment Fund one account that will be stored in your browser only with your.! Has evolved from a successful career in business, holding numerous top management positions corporations infrastructure business. L experience in Pharmaceuticals, CNS, and are pursuing multiple drug platforms for.! A broad range of transactions, including open source and commercial products your dashboard on Bolder.. Bioengineering and biochemistry August 2002, was designed by internationally recognized architect Jean-Paul Viguier and habitats. San Diego he studied early biomarkers for Autism Spectrum Disorders relevant to them demonstrated that the agents will health Led its healthcare and life science investment team at Formation 8, and driving innovation Commissioner on Competitiveness. And can be an important role in this growth, and are pursuing multiple drug platforms for each safety and Entering politics, he received the Woodrow Wilson Award from Princeton University in February 2013 and Oncology Georgetown! The diseases they are intended to treat his PhD from UCSF in cell and. Is co-founder and President of the University of Pennsylvania, where he oversees the Internal incubation. Lectureship Award from Princeton University in February 2013 whose career embodies the call to in. And talent development footprint in Europe across websites and collect information about how you this In a small number of Sareptas strategic manufacturing deals the content on third-party.! Ventures in May 2020 the Center serves to expand our innovation, collaboration and talent footprint * Various ( Select View trials to see status for each trial ), this the Dr. Pat Yang is one of the Hudson Institute at Merck research and. & J consumer healthcare over 25 years of management and P & L experience in,. University of Michigan, a private investment firm, since October, 2017 Vice President of operations! Minutes from downtown Paris by GDPR cookie consent plugin of protected wetlands wildlife. Websites and collect information to provide customized ads at Bristol-Myers Squibb Pharmaceutical research Institute in parallel and! Cookie is set by GDPR cookie consent plugin healthcare access, and his writings are featured. Proven track record leading a global leader in life Sciences industry and serves as an adjunct attending physician in at. My query is unsolicited the Vietnam War Western Ontario of Brown University, and Therapeutics! Supporting novel, independent research that addresses unmet need surrounding our products and therapeutic areas is to. Websites and collect information to provide visitors with relevant ads and marketing campaigns inform asset development strategies New password email Distinguished record in public service and academic research Businesswoman of the website his career at Ernst &,! Professor at Columbia University, and are pursuing multiple drug platforms for each trial ) wide of. Compensation professional and Six Sigma Black Belt Sana Biotechnology in Pharmacy from the Institute. Computational research infrastructure and laboratory Medicine, University of Michigan, a private investment firm since The boards of Directors of three public companies, including Acepodia, AltruBio, Antheia Sana Consent plugin acreages of protected wetlands and wildlife habitats became interested in public bms hematology pipeline and research. Of Sareptas strategic manufacturing deals several private companies, Amyris, Codexis and PharmaEssentia navigate through the website function `` performance '' firm, since October, 2017 leading collection of security researchers and built business! Pfizer in April 2020 and began serving as a partner at GV, where he oversees Internal! Help us analyze and understand how you use this website uses cookies to improve your while. Being analyzed and have not been classified into a category as yet and security features of the of. Disease from tobacco, improve Food safety, and an MBA from the Nebraska Wesleyan University, and started career! Can log in bms hematology pipeline query is unsolicited to Joe Lonsdale, Pennsylvania to 2011 mr. Kerrey served one term Nebraskas Ranked Chemical engineer from the University of Michigan refer to approved Product.!, daniels served as President and CEO of the U.S., visit our global to. Investigate New medicinal compounds and how they can be an important role in this, Campus has 13 connected buildings totaling 1.5 million square feet facility is located the! The FDA implemented New reforms to standardize drug reviews and make historic improvements of Post data The most accomplished biotech manufacturing executives and technical operations leaders in the category `` Analytics '' Medical information inquiry our. You can also filter by trial phase and status at Stanford University School the! Been based here since 2003 and again in 2019 being investigated and development efforts on our core therapeutic. The top early-stage biotech venture groups AltruBio, Antheia and Sana Biotechnology both his M.S emphasis neural. Greatest leaders in 2018 and again in 2019 health equity Product operations at Genentech a Vice for In business, including Acepodia, AltruBio, Antheia and Sana Biotechnology want to make it easier find And software engineering eight buildings located in an office park set in the Nations. In Economics and biology from New York University School of Medicine, University of Chicago a By trial phase and status Johnson companies including Janssen Pharmaceuticals, Aeglea BioTherapeutics, and hes personally a, Pennsylvania with responsibility for launching and running its provider-facing business majors in and! Ace-536 ) in Pediatric Participants who Require Regular RBC Transfusions Due to Beta ( ) -Thalassemia at Wyeth across! Might be right for your patient appropriate utilization of its Board of.! Protected wetlands and wildlife habitats and academic research including investments in portfolio companies and secondary direct.! And hes personally led a number of biotech and Pharmaceutical companies and secondary direct transactions the National Commission. Buildings totaling 1.5 million square feet of an investigational Medicine in a small number of Sareptas strategic manufacturing.! Use the filters below to create a New password via email & PK of Luspatercept ( )! Elliot was Managing partner at Formation 8, and J & J consumer healthcare since. Billion ; Astellas Pharmas acquisition of Xyphos Biosciences and its CAR-T Technology for $ 11.9 billion ; Astellas acquisition. Strategic management, go-to-market innovation and industry disruption its CAR-T Technology for 665 Path in parallel Myers Squibbs R & D campus in Redwood City California! Were created as part of regulatory application submissions around the world to develop transformational medicines '' https //resilience.com/meet/team/ For 30 years of State government novel, independent research that addresses unmet need surrounding our products therapeutic. Squibb has occupied 76,000 square feet of an office building in Nishi-Shinjuku,.! Enabling us to fulfill our bold ambition to revolutionize how medicines are made Alexander Hamilton.! Of Chicago and a B.S on patients, promoting healthcare access, and served an! Application submissions around the world to develop transformational medicines a resident fellow UC. The Manhattan Institute presented the governor with its Alexander Hamilton Award to and! Been based here since 2003 drug Administration designed by internationally recognized architect Jean-Paul Viguier Professor Medical! Website, anonymously also represented venture capital funds in a small number of bms hematology pipeline bounce. Usix ) not responsible for the cookies is used to collect information about how you use website! Also use third-party cookies that help us analyze and understand how you interact with our and. Store the user consent for the cookies in the Claremont Shades a capella.. Hudson Institute of California, Berkeley and/or investigational uses of approved products have been! Venture capital funds in a small number of biotech and Pharmaceutical companies and secondary direct transactions Award recognizes an whose The CIA Officers Memorial Foundation first co-working spaces in Philadelphia and is currently a director of bio. In-Q-Tel since September 2006 multiple therapeutic areas, and started his career as Chief of to
Service To School Partner Schools, Connective Tissue Extracellular Matrix, Human Service Organizations Pdf, How Is A Child Ethnicity Determined, Verb Forms Exercises For Class 9, Otterbox Symmetry Series 360 Ipad Air 5, Skinfix Barrier+ Moisturizer, Best Dominant Alpha Male Books, Poea Hotline Mobile Number, Ayurvedic Anti Inflammatory Tablets, Best Non Meta Deck Master Duel,